GPA announced on Wednesday (20) the sale of its entire stake in Stix Fidelidade e Inteligência to RD Saúde for R$23 million, ending the loyalty program joint venture between the companies. The transaction involves 66.7% of the platform's share capital. ✓
Press quotes (1)
"O GPA (PCAR3) anunciou nesta quarta-feira (20) a venda da totalidade de sua participação na Stix Fidelidade e Inteligência para a RD Saúde (RADL3). Segundo a companhia, foi celebrado um contrato para a alienação dos 66,7% detidos pelo GPA na Stix, encerrando a joint venture de programas de fidelidade formada entre as empresas"
According to a market statement, the operation still depends on fulfilling precedent conditions, including approval from the Administrative Council for Economic Defense (Cade). GPA stated the decision aligns with its portfolio management strategy and will allow focus on core activities. ✓
Press quotes (1)
"A operação prevê pagamento total de R$ 23 milhões ao GPA e ainda depende do cumprimento de condições precedentes, incluindo aprovação do Conselho Administrativo de Defesa Econômica (Cade)"
Should the transaction be completed, the companies will establish a transition agreement to preserve customer experience during the migration period. The Stix program will be maintained under conditions equivalent to current operations, including point accumulation and redemption by GPA customers. ✓
Press quotes (1)
"Caso a operação seja concluída, o GPA, a Stix e a RD Saúde celebrarão instrumento particular para estabelecer um período de transição, com o objetivo de preservar a experiência dos clientes nas lojas. Durante esse período, o GPA e a RD manterão o programa em condições operacionais equivalentes às praticadas atualmente, incluindo a possibilidade de acúmulo e resgate de pontos Stix pelos clientes do GPA"
The sale occurs amid GPA's financial pressure, which reported an adjusted net loss of R$333 million in the first quarter, with analysts concerned about deteriorated cash flow and impacts from the out-of-court restructuring process. ✓
Press quotes (1)
"No balanço mais recente, do primeiro trimestre, o GPA reportou prejuízo líquido ajustado de R$ 333 milhões, pressionado pelo aumento das despesas financeiras. Analistas seguem preocupados com a pressão financeira, o fluxo de caixa deteriorado e os impactos do processo de recuperação extrajudicial"
The transaction involves the sale of 66.7% of Stix for R$23 million and ends the joint venture between GPA and RD Saúde
The operation depends on Cade approval as a precedent condition
Covered by only some sources, or where the accounts diverge.
Covered by only some sources (1)
GPA reported R$333 million loss in Q1 with analysts concerned about financial pressure
-
What is RD Saúde's specific strategic rationale for acquiring the Stix stake and why did GPA choose to divest the asset now?
Why it's still unknown: Companies did not detail specific strategic motives beyond generic statements about portfolio management
-
What is the expected timeline for Cade approval and are there other regulatory requirements beyond antitrust approval?
Why it's still unknown: No specific timelines for fulfilling precedent conditions were disclosed
-
How does the R$23 million price compare to fair value of the stake considering loyalty program sector multiples?
Why it's still unknown: No source presented valuation analysis or comparable multiples
-
What is Stix's recent financial performance and its contribution to GPA's results?
Why it's still unknown: No specific joint venture results were disclosed